Welcome to Chemocentryx.com - You are being redirected...

chemocentryx.com

Description: Chemocentryx. Positive topline data from pivotal Phase III ADVOCATE trial demonstrates avacopan’s superiority over standard of care in...

Google PR 0

Trustworthiness Good
Avg. Daily Visitors 505

Child Safety Unknown
Avg. Daily Pageviews 1 009

Privacy Good

You are being redirected...

Chemocentryx.com: get to the top rated Chemocentryx pages and content popular with USA-based Chemocentryx.com users or check the following digest to find out more. Chemocentryx.com is a malware-free website without age restrictions, so you can safely browse it. It seems that Chemocentryx team are just starting to conquer the social media and they have already achieved a promising result — 8 user activities so far (LinkedIn dominates with around 95% of all user reactions). Chemocentryx.com is hosted with Sucuri in United States. Chemocentryx traffic is estimated at around 15.1K visits per month.

Visit chemocentryx.com

Domain info

Location:	United States
Registrant:	Domain Administration (Amgen Inc.)
Hosted by:	Sucuri
Registrar:	MarkMonitor Inc.
Subnetworks:	192.124.249.158

Alexa's Traffic Estimates & Trends

Traffic Rank:	827 869
Month Average Daily Reach:	0.000019	-35.9%
Month Average Daily Pageviews:	0.000001	-62.8%

More details from Alexa

Social Media Activities

Facebook likes: -
Twitter mentions: -
Google pluses: -
LinkedIn mentions: 8
Pinterest pins: -
StumbleUpon views: -

Web Safety

This website is malware-free.
Status ok

See Google Transparency Report

Sites associated with the same registrant

Whois

Expand

Chemocentryx.com popular pages to visit

ChemoCentryx – Orphan and Rare Diseases Orphan and Rare Diseases ANCA Associated Vasculitis (AAV) ANCA Associated Vasculitis (AAV) is a rare, severe, and often fatal autoimmune disease that is caused by autoantibodies called anti-neutrophil...

You are being redirected... People Deserve Better Medicine At ChemoCentryx, we believe our patients deserve more than the standard of care available today. So, we are developing our broad portfolio of new medicines using a novel...

ChemoCentryx – Vercirnon Our drug candidate vercirnon (also known as Traficet-EN or CCX282), which targets the chemokine receptor known as CCR9, is a Phase III-ready drug candidate for the potential treatment of patients with...